Clinical Trial Update: Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia [Phase 2]

View source ↗

Summary

Phase 2 study of ruxolitinib (INCB018424) in polycythemia vera and essential thrombocythemia was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myeloproliferative Neoplasm (MPN) | Phase 2 | Status: TERMINATED | Results posted: 2012-02-24